DK0661973T3 - Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade - Google Patents

Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade

Info

Publication number
DK0661973T3
DK0661973T3 DK93923724T DK93923724T DK0661973T3 DK 0661973 T3 DK0661973 T3 DK 0661973T3 DK 93923724 T DK93923724 T DK 93923724T DK 93923724 T DK93923724 T DK 93923724T DK 0661973 T3 DK0661973 T3 DK 0661973T3
Authority
DK
Denmark
Prior art keywords
nmda receptor
mediated neuronal
procedure
receptor complex
mammal
Prior art date
Application number
DK93923724T
Other languages
English (en)
Inventor
Stuart A Lipton
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/949,342 external-priority patent/US5234956A/en
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of DK0661973T3 publication Critical patent/DK0661973T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK93923724T 1992-09-22 1993-09-22 Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade DK0661973T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/949,342 US5234956A (en) 1991-04-19 1992-09-22 Method of preventing NMDA receptor complex-mediated neuronal damage
US08/025,028 US5455279A (en) 1991-04-19 1993-03-02 Regimen method of mediating neuronal damage using nitroglycerine

Publications (1)

Publication Number Publication Date
DK0661973T3 true DK0661973T3 (da) 2006-10-30

Family

ID=26699179

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93923724T DK0661973T3 (da) 1992-09-22 1993-09-22 Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade

Country Status (8)

Country Link
US (3) US5455279A (da)
EP (1) EP0661973B1 (da)
AT (1) ATE330606T1 (da)
AU (1) AU5348194A (da)
DE (1) DE69334035T2 (da)
DK (1) DK0661973T3 (da)
ES (1) ES2264122T3 (da)
WO (1) WO1994006428A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486621A4 (en) * 1989-08-09 1993-03-31 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5849895A (en) 1993-04-20 1998-12-15 Sibia Neurosciences, Inc. Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US5807847A (en) * 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU4030097A (en) * 1996-09-03 1998-03-26 Yeda Research And Development Co. Ltd. Central nervous system-derived immune privilege factor and uses thereof
WO1998043621A1 (en) * 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
AU8399098A (en) * 1997-07-11 1999-02-08 Johns Hopkins University School Of Medicine, The Nitric oxide inhibits rhinovirus infection
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
JPH11217330A (ja) * 1998-01-30 1999-08-10 Sumitomo Pharmaceut Co Ltd 神経栄養因子分泌促進剤
EP1013272A1 (en) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Manipulation of the activity of a nitric oxide radical production pathway for the treatment of diseases associated with the presence of oxygen free radicals
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
US6255280B1 (en) 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
GB9908175D0 (en) * 1999-04-09 1999-06-02 Lilly Co Eli Method of treating neurological disorders
WO2000064440A1 (en) * 1999-04-22 2000-11-02 Department Of The Army, U.S. Government Treatment of and/or prophylaxis against brain and spinal cord injury
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
US6339102B1 (en) * 1999-06-09 2002-01-15 The United States Of America As Represented By The Secretary Of The Army Method and composition for treating and preventing retinal damage
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
EA005649B1 (ru) * 2000-08-11 2005-04-28 Дэвид Р. Уитлок Композиции, содержащие аммиакокисляющие бактерии, увеличивающие продуцирование окиси азота и предшественников окиси азота, и способы их использования
BR0116001A (pt) * 2000-12-07 2004-07-06 Neuromolecular Inc Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda
EP1852113A3 (en) * 2000-12-07 2008-03-12 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
WO2003057380A2 (en) * 2002-01-11 2003-07-17 Whitlock David R Compositions including ammonia oxidizing bacteria and methods of using same
US20030229114A1 (en) * 2002-04-04 2003-12-11 Rosenberg Paul A. Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
US20050148673A1 (en) * 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
JP2007508247A (ja) * 2003-09-26 2007-04-05 ホイットロック，デービッド，アール． アンモニア酸化細菌の使用方法
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
ES2483126T3 (es) 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
WO2007116458A1 (ja) * 2006-03-30 2007-10-18 Tohru Hasegawa 神経変性疾患治療薬
JP5228912B2 (ja) * 2006-09-08 2013-07-03 三菱瓦斯化学株式会社 高血圧改善剤
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
IT1398507B1 (it) * 2009-01-13 2013-03-01 Giellepi Chemicals S P A Composizione per il trattamento di neuropatie
US9023890B2 (en) * 2009-12-02 2015-05-05 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
UY33203A (es) 2010-01-27 2011-08-31 Takeda Pharmaceutical Medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígeno
US9452117B2 (en) 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
WO2014117089A1 (en) 2013-01-25 2014-07-31 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
KR102607213B1 (ko) 2014-04-15 2023-11-30 에이오바이오미 엘엘씨 암모니아-산화 니트로소모나스 유트로파 균주 d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
US4064139A (en) * 1975-04-07 1977-12-20 Merck & Co., Inc. Substituted 9,10-dihydroanthracen-9,10-imines
US4374838A (en) * 1977-09-19 1983-02-22 Merck & Co., Inc. Dibenzo[a,d]cycloocten-5,12-(and 6,12)-imines
US4399141A (en) * 1977-09-19 1983-08-16 Merck & Co., Inc. 5-Alkyl or hydroxyalkyl substituted-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines and anticonvulsant use thereof
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4513137A (en) * 1981-04-09 1985-04-23 The University Of Akron Iodonium salts
US4351847A (en) * 1981-06-26 1982-09-28 Pennwalt Corporation Antiviral alpha, alpha-dialkyl adamantylethylamines
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists
US4736048A (en) * 1986-06-04 1988-04-05 Dow Corning Corporation Pressure sensitive adhesive release liner and fluorosilicone compounds, compositions and method therefor
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
ATE191145T1 (de) * 1987-01-23 2000-04-15 Gen Hospital Corp Hydralazin zur topischen behandlung von glaukom
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
DE58905637D1 (de) * 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
EP0486621A4 (en) * 1989-08-09 1993-03-31 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5264371A (en) * 1989-11-22 1993-11-23 Neurex Corporation Screening method for neuroprotective compounds
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
DE69229598T2 (de) * 1991-04-19 1999-11-04 Children's Medical Center Corp., Boston Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden

Also Published As

Publication number Publication date
ES2264122T3 (es) 2006-12-16
EP0661973A4 (en) 1999-12-22
DE69334035T2 (de) 2006-12-28
DE69334035D1 (de) 2006-08-03
EP0661973A1 (en) 1995-07-12
WO1994006428A1 (en) 1994-03-31
US5801203A (en) 1998-09-01
AU5348194A (en) 1994-04-12
EP0661973B1 (en) 2006-06-21
US5747545A (en) 1998-05-05
US5455279A (en) 1995-10-03
ATE330606T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
DK0661973T3 (da) Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade
EP0313305A3 (en) Photoprotection compositions comprising chelating agents
IS4185A (is) Hliðstæð aðferð til framleiðslu fenýlsúlfonylamino-pýrimidines afleiða
DK0557385T3 (da) Topiske sammensætninger til transdermal afgivelse af prodrug-derivater af morfin
ES2134804T3 (es) Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
BG40955A3 (en) Acaricide means and method for protection from acars
FI932254A7 (fi) Menetelmä dipalmitoyylifosfaridyylikoliinidispersioiden antamiseksi
ATE121086T1 (de) Sulfonylbenzyl-substituierte benzo- und pyridopyridone.
ATE164159T1 (de) Substituierte triole
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
DE59200469D1 (de) Verfahren zum mehrstufigen bearbeiten von zähnen an sägeblättern sowie sägenbearbeitungsmaschine zum durchführen des verfahrens.
DK0607278T3 (da) Fremgangsmåde til forstærkning af tarmabsorption
NO890046L (no) Disubstituerte pyridiner.
DE69217003D1 (de) N-phenyl-benzamide zum schutz vor den schädlichen wirkungen von ultraviolettlicht
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
DK16389D0 (da) Anvendelse af en blanding til behandling af alopecia
FI891473A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi
DK0802796T3 (da) Kyllingeanæmimiddel-slagtekyllingevaccine
JPS5412688A (en) Manufacture of photo coupler
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
DK211189A (da) Fremgangsmaade til fremstilling af 5-chlor-3-chlorsulfonyl-2-thiophencarboxylsyreestere
AU7358691A (en) Tenidap as an inhibitor of the release of elastage by neutrophils
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
JPS5233237A (en) Elevator control system
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis